B.J. Rimel

1. NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer
   2023/12/21 by B.J. Rimel, Bobbie J. Rimel, Danielle Enserro +17 · 10 citations
   Medicine · #PARP inhibition in cancer therapy #Endometrial and Cervical Cancer Treatments #Prostate Cancer Treatment and Research